文献速递临床试验与 GCP流行病学与生物统计

头孢吡肟与哌拉西林-他唑巴坦用于急性感染住院成人:ACORN随机临床试验

Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

ACORN随机临床试验在美国一个学术医疗中心纳入2511例因急性感染在急诊科或内科ICU启动抗假单胞菌抗生素的成人,1:1随机接受头孢吡肟或哌拉西林-他唑巴坦。主要结局(14天内急性肾损伤最高分期或死亡)两组无显著差异(OR 0.95,95%CI 0.80-1.13,P=0.56)。头孢吡肟组14天内无谵妄和昏迷的存活天数更少(OR 0.79,95%CI 0.65-0.95),作者结论为哌拉西林-他唑巴坦未增加急性肾损伤或死亡,头孢吡肟导致更多神经功能障碍。

要点

  • 主要结局14天内急性肾损伤最高分期或死亡两组无显著差异(OR 0.95,95%CI 0.80-1.13,P=0.56)。
  • 头孢吡肟组14天内无谵妄和昏迷的存活天数更少(均数11.9天 vs 12.2天;OR 0.79,95%CI 0.65-0.95)。
  • 14天主要不良肾脏事件发生率两组无差异(10.2% vs 8.8%;绝对差1.4%,95%CI -1.0%至3.8%)。

核心结论

  • 在住院成人中,哌拉西林-他唑巴坦未增加急性肾损伤或死亡的发生率。
  • 头孢吡肟导致更多神经功能障碍。

研究设计与样本

  • ACORN随机临床试验在美国一个学术医疗中心开展,纳入因急性感染在急诊科或内科ICU启动抗假单胞菌抗生素的成人。
  • 纳入时间为2021年11月10日至2022年10月7日,末次随访日期为2022年11月4日。
  • 患者按1:1比例随机分配至头孢吡肟组或哌拉西林-他唑巴坦组。
  • 主要分析纳入2511例患者(中位年龄58岁,IQR 43-69岁;女性42.7%;非西班牙裔黑人16.3%;西班牙裔5.4%;94.7%在急诊科入组;77.2%入组时正在使用万古霉素)。

主要发现

  • 主要结局(14天内急性肾损伤最高分期或死亡)在头孢吡肟组与哌拉西林-他唑巴坦组间无显著差异:头孢吡肟组3期急性肾损伤85例(n=1214,7.0%)、死亡92例(7.6%),哌拉西林-他唑巴坦组3期急性肾损伤97例(n=1297,7.5%)、死亡78例(6.0%)(OR 0.95,95%CI 0.80-1.13,P=0.56)。
  • 14天主要不良肾脏事件发生率两组无差异:头孢吡肟组124例(10.2%)vs 哌拉西林-他唑巴坦组114例(8.8%),绝对差1.4%(95%CI -1.0%至3.8%)。
  • 头孢吡肟组14天内无谵妄和昏迷的存活天数更少:均数(SD)11.9(4.6)天 vs 哌拉西林-他唑巴坦组12.2(4.3)天(OR 0.79,95%CI 0.65-0.95)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cefepime and piperacillin-tazobactam are commonly administered to hospitalized adults for empirical treatment of infection. Although piperacillin-tazobactam has been hypothesized to cause acute kidney injury and cefepime has been hypothesized to cause neurological dysfunction, their comparative safety has not been evaluated in a randomized clinical trial. OBJECTIVE: To determine whether the choice between cefepime and piperacillin-tazobactam affects the risks of acute kidney injury or neurological dysfunction. DESIGN, SETTING, AND PARTICIPANTS: The Antibiotic Choice on Renal Outcomes (ACORN) randomized clinical trial compared cefepime vs piperacillin-tazobactam in adults for whom a clinician initiated an order for antipseudomonal antibiotics within 12 hours of presentation to the hospital in the emergency department or medical intensive care unit at an academic medical center in the US between November 10, 2021, and October 7, 2022. The final date of follow-up was November 4, 2022. INTERVENTIONS: Patients were randomized in a 1:1 ratio to cefepime or piperacillin-tazobactam. MAIN OUTCOMES AND MEASURES: The primary outcome was the highest stage of acute kidney injury or death by day 14, measured on a 5-level ordinal scale ranging from no acute kidney injury to death. The 2 secondary outcomes were the incidence of major adverse kidney events at day 14 and the number of days alive and free of delirium and coma within 14 days. RESULTS: There were 2511 patients included in the primary analysis (median age, 58 years [IQR, 43-69 years]; 42.7% were female; 16.3% were Non-Hispanic Black; 5.4% were Hispanic; 94.7% were enrolled in the emergency department; and 77.2% were receiving vancomycin at enrollment). The highest stage of acute kidney injury or death was not significantly different between the cefepime group and the piperacillin-tazobactam group; there were 85 patients (n = 1214; 7.0%) in the cefepime group with stage 3 acute kidney injury and 92 (7.6%) who died vs 97 patients (n = 1297; 7.5%) in the piperacillin-tazobactam group with stage 3 acute kidney injury and 78 (6.0%) who died (odds ratio, 0.95 [95% CI, 0.80 to 1.13], P = .56). The incidence of major adverse kidney events at day 14 did not differ between groups (124 patients [10.2%] in the cefepime group vs 114 patients [8.8%] in the piperacillin-tazobactam group; absolute difference, 1.4% [95% CI, -1.0% to 3.8%]). Patients in the cefepime group experienced fewer days alive and free of delirium and coma within 14 days (mean [SD], 11.9 [4.6] days vs 12.2 [4.3] days in the piperacillin-tazobactam group; odds ratio, 0.79 [95% CI, 0.65 to 0.95]). CONCLUSIONS AND RELEVANCE: Among hospitalized adults in this randomized clinical trial, treatment with piperacillin-tazobactam did not increase the incidence of acute kidney injury or death. Treatment with cefepime resulted in more neurological dysfunction. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05094154.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Qian ET, Casey JD, Wright A, et al. Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial. JAMA. 2023. PMID: 37837651. doi:10.1001/jama.2023.20583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。